Uterine Cancer Clinical Trials 2023
Browse 35 Uterine Cancer Medical Studies Across 163 Cities
301 Uterine Cancer Clinics
Reviewed by Michael Gill, B. Sc.
10 Uterine Cancer Clinical Trials Near Me
Top Hospitals for Uterine Cancer Clinical Trials
Memorial Sloan Kettering Cancer Center
New York
4Active Trials
14All Time Trials for Uterine Cancer
2000First Uterine Cancer Trial
Duke University Medical Center
Durham
2Active Trials
5All Time Trials for Uterine Cancer
2006First Uterine Cancer Trial
Northwest Cancer Specialists, P.C.
Vancouver
2Active Trials
2All Time Trials for Uterine Cancer
2021First Uterine Cancer Trial
Top Cities for Uterine Cancer Clinical Trials
Uterine Cancer Clinical Trials by Phase of TrialN/A Uterine Cancer Clinical Trials
Uterine Cancer Clinical Trials by Age Group11Active Uterine Cancer Clinical Trials
11Number of Unique Treatments
9Number of Active Locations
18+ Uterine Cancer Clinical Trials
Most Recent Uterine Cancer Clinical Trials35Active Uterine Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Treatment Name
Active Uterine Cancer Clinical Trials
All Time Trials for Uterine Cancer
First Recorded Uterine Cancer Trial
trastuzumab
1
1
2021
Seribantumab
1
1
2020
Intraperitoneal Chemotherapy
1
1
2020
Single Arm - Pembrolizumab
1
1
2019
AZD1775
1
1
2018
Treatment
Year
Sponsor
Atezolizumab
2017
Gradalis, Inc.
About The Author
Michael Gill - B. Sc.
First Published: October 21st, 2021
Last Reviewed: September 17th, 2023
References1 Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. https://pubmed.ncbi.nlm.nih.gov/324637412 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan;140(1):161-6. doi: 10.1016/j.ygyno.2015.11.003. Epub 2015 Nov 14. https://pubmed.ncbi.nlm.nih.gov/265864153 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan;140(1):161-6. doi: 10.1016/j.ygyno.2015.11.003. Epub 2015 Nov 14. Review. https://pubmed.ncbi.nlm.nih.gov/265864154 Leung E, Gladwish AP, Davidson M, Taggar A, Velker V, Barnes E, Mendez L, Donovan E, Gien LT, Covens A, Vicus D, Kupets R, MacKay H, Han K, Cheung P, Zhang L, Loblaw A, D'Souza DP. Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial. JAMA Oncol. 2022 Apr 14. doi: 10.1001/jamaoncol.2022.0362. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/354206955 Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8. https://pubmed.ncbi.nlm.nih.gov/351338716 Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 Feb;6:e2100424. doi: 10.1200/PO.21.00424. https://pubmed.ncbi.nlm.nih.gov/351389197 Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007 Oct;31(10):1578-85. doi: 10.1097/PAS.0b013e31804375b8. https://pubmed.ncbi.nlm.nih.gov/178957618 Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006 Jan;43(1):18-27. Epub 2005 Jun 3. https://pubmed.ncbi.nlm.nih.gov/159370709 Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA; NCI-MATCH team. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 Nov 20;38(33):3883-3894. doi: 10.1200/JCO.19.03010. Epub 2020 Oct 13. https://pubmed.ncbi.nlm.nih.gov/3304861910 Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. https://pubmed.ncbi.nlm.nih.gov/32463741